Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma and Vectura ally on Ellipta rivals

Executive Summary

Hikma has announced a global development and marketing collaboration deal with Vectura aimed at developing generic versions of GlaxoSmlithKline’s (GSK’s) Ellipta respiratory portfolio. The agreement on rivals to Ellipta – which builds on an existing collaboration between the two firms to develop a generic version of GSK’s Advair Diskus (fluticasone/salmeterol) – will use Vectura’s proprietary ‘open-inhale-close’ dry-powder inhaler device.

You may also be interested in...



Hikma Is Prepared For Tougher Pricing Environment In 2022

Hikma is prepared for additional competitors on key products as well as growing price pressure in the US, CEO Siggi Olafsson tells Generics Bulletin in the second part of an exclusive interview.

Hikma Still Sees Value In Generic Advair Despite Teva’s US Approval

Hikma expects healthy prospects for its US Advair generic in 2022, despite rival Teva recently receiving FDA approval for its own version. Meanwhile, Hikma CEO Siggi Olafsson also outlined expectations for generic competition on icosapent amid ongoing API shortages.

Philip Morris Closes In On Vectura As £1.1bn Offer Passes Threshold

Philip Morris once again pledged to up R&D in Vectura after its £1.1bn takeover offer for the UK-based inhalation specialist became unconditional, following the tobacco giant’s acrimonious face-off with private equity Carlyle earlier this year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB001471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel